Roche Holding plans to move on to final tests of aleglitazar in the second half of this year after the diabetes drug helped control blood-glucose levels in a 300-patient trial. Roche hopes the drug, which is being developed for diabetics with an increased risk of heart disease, will be ready for regulatory filing after 2012.

Full Story:

Related Summaries